According to GlobalData’s medical device pipeline database, 358 Cardiac Disease devices are in various stages of development globally. GlobalData’s report Cardiac Disease provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Of these devices, 115 are in active development, while the remaining 244 are in an inactive stage of development. There are 68 products in the early stages of development, and the remaining 47 are in the late stages of development.
This category includes Cardiac Marker Tests segment.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Cardiac Disease pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Cardiac Disease devices. Overall, most of these Cardiac Disease pipeline devices are being developed by private entities.
Key players involved in the active development of Cardiac Disease include Upstream Medical Technologies, Roche Diagnostics International, Siemens Healthcare Diagnostics, Abbott Diagnostics, China Medical Technologies, Guangzhou Wondfo Biotech, SomaLogic, Ortho Clinical Diagnostics, Cavadis and Beckman Coulter.
For a complete picture of the developmental pipeline for Cardiac Disease devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.